Cantitate/Preț
Produs

Docking Studies of Bcr-Abl And c-Abl by Structural Analogues of GNF-2

Autor Drushti Bhatt, Sairam Kalapatapu, Yogesh Jasarai
en Limba Engleză Paperback – 6 mai 2012
In an attempt to search for new pharmacological approach to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, allosteric inhibitors had been discovered. The ATP-competitive inhibitors nilotinib and dasatinib, which bind to catalytically different conformation of the Abl kinase domain, had been approved for the targeting most of imatinib-resistant CML, fail to effectively suppress the Bcr-Abl activity of T351I (gatekeeper) mutation. The GNF-2, class of compound that inhibits Bcr-Abl kinase activity through an allosteric non-ATP competitive mechanism. The GNF-2 binds to myristate-binding -site of Abl, leading to change in structure of ATP-binding-site. The GNF-5, an analogue of GNF-2 has appropriate pharmacokinetic properties, used in simultaneous binding of ATP-binding-inhibitors imatinib and nilotinib to obscure resistant mutation in Bcr-Abl. The aim of this work is to analyse the different structural analogues of GNF-2, which can be used as therapeutic agent to treat Chronic Myelogenous Leukemia (CML).
Citește tot Restrânge

Preț: 31481 lei

Nou

Puncte Express: 472

Preț estimativ în valută:
6024 6318$ 5024£

Carte tipărită la comandă

Livrare economică 07-21 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783659106972
ISBN-10: 3659106976
Pagini: 96
Dimensiuni: 152 x 229 x 6 mm
Greutate: 0.15 kg
Editura: LAP LAMBERT ACADEMIC PUBLISHING AG & CO KG
Colecția LAP Lambert Academic Publishing

Notă biografică

Pursuing M.Phil Bioinformatics from Gujarat University, Ahmedabad, India. Completed research work on cancer biology especially Chronic myelocytic leukaemia(CML) and Acute myelocytic leukaemia(AML). Presently working on the project miRNA(microRNA), targeting to treat disease in cellular level.